Few UK patients suitable for ‘breakthrough’ Alzheimer’s drugs
Few people in the UK with early stage Alzheimer’s disease are likely to be suitable for the latest drugs which aim to halt progress of the condition, a new study has found. The research is published in the Journal of Neurology Neurosurgery & Psychiatry. Disease-modifying drugs, lecanemab and donanemab, slow cognitive decline in people with early […]